Alex Racco, DO
Cardiovascular Disease · Staten Island, NYNPI 1497783054
Payments from drug & device makers
Across 675 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- GSK$1K
- Novo Nordisk$1K
- Lilly USA, LLC$919
- Amgen$862
- plus $4K from 38 others
What the payments were for
- Food & beverage$11,87499%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,988 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 249 | $310,967 |
| MounjaroTirzepatide | 174 | $278,379 |
| OzempicSemaglutide | 169 | $235,493 |
| JanuviaSitagliptin Phosphate | 124 | $134,408 |
| JardianceEmpagliflozin | 94 | $126,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $107,788 |
| TrulicityDulaglutide | 47 | $86,749 |
| RybelsusSemaglutide | 53 | $81,964 |
| FarxigaDapagliflozin Propanediol | 70 | $79,650 |
| XareltoRivaroxaban | 69 | $77,891 |
| ProliaDenosumab | 38 | $66,869 |
| JanumetSitagliptin Phos/Metformin Hcl | 50 | $45,785 |
| EntrestoSacubitril/Valsartan | 27 | $42,838 |
| OxycontinOxycodone Hcl | 11 | $31,295 |
| Repatha SureclickEvolocumab | 38 | $28,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $919 | $365,127221 claims |
| PfizerEliquis, Nurtec Odt | $565 | $334,340261 claims |
| Novo NordiskOzempic, Rybelsus | $1,101 | $317,457222 claims |
| MerckJanuvia, Janumet, Janumet Xr | $465 | $204,268207 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta | $1,227 | $163,345220 claims |
| Boehringer IngelheimJardiance, Tradjenta | $339 | $144,880115 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $1,432 | $108,881103 claims |
| Johnson & JohnsonXarelto, Invokana | $164 | $95,15287 claims |
| AmgenProlia | $862 | $66,86938 claims |
| NovartisEntresto, Diovan | $456 | $56,64445 claims |
| AbbVieLinzess, Synthroid | $2,035 | $26,570192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Staten Island
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.